← Back to Clinical Trials
Recruiting NCT07256119

NCT07256119 Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07256119
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Prevention
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-08-06
Primary Completion 2025-12-28

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Alpha Lipoic Acid

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-08-06 with a primary completion date of 2025-12-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

the purpose of this study is to evaluate the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients

Eligibility Criteria

Inclusion Criteria: * Women aged ≥18 years. * Histologically confirmed invasive, early-stage breast carcinoma scheduled for adjuvant radiotherapy. * Receiving total radiation dose of 40 Gy for 15 sessions. Exclusion Criteria: * Prior exposure to radiotherapy. * Inflammatory or metastatic breast carcinoma. * Patients with connective tissue disorders. * Patients with skin inflammatory diseases (e.g. ectopic dermatitis). * Patients with known allergy or hypersensitivity to alpha lipoic acid. * Concomitant use of nonsteroidal anti-inflammatory drugs, corticosteroids, or antioxidant medications. * Patients who will fail to sign the written consent.

Contact & Investigator

Central Contact

Rana Mohamed Elsayed Kelany Abdelkader

✉ rana.mohamed18@pharma.asu.edu.eg

📞 00201023262639

Principal Investigator

Rana Mohamed Elsayed Kelany Abdelkader

PRINCIPAL INVESTIGATOR

Faculty of Pharmacy, Ain Shams University

Frequently Asked Questions

Who can join the NCT07256119 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 75 Years, studying Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07256119 currently recruiting?

Yes, NCT07256119 is actively recruiting participants. Contact the research team at rana.mohamed18@pharma.asu.edu.eg for enrollment information.

Where is the NCT07256119 trial being conducted?

This trial is being conducted at Zagazig, Egypt.

Who is sponsoring the NCT07256119 clinical trial?

NCT07256119 is sponsored by Ain Shams University. The principal investigator is Rana Mohamed Elsayed Kelany Abdelkader at Faculty of Pharmacy, Ain Shams University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology